Purpose 1 Study

Summary: A study evaluating the efficacy of Lenacapavir (LEN) and Emitricitabine (F/TDF)/Tenofovir Alafenamide (F/TAF) in preventing HIV infection among adolescent girls and young women (AGYW)

Study Sponsor: Gilead Sciences, Inc

Study Principle Investigator: Dr. Godfrey Kigozi

Study Site: AMBSO -Masaka Research Site

Update: Currently at Open Label Extension Phase (OLE)

Interim Results:
Out of the 5338 HIV negative cisgender females 16-25 years recruited, 55HIV incident cases (0 Len/2134 participants. 39 F/TAF/2136, 16F/TDF/1068.

High level interaction during the set up phases of the Purpose 1 Trial

Investigators interactions during the Purpose 1 SIV

Implications